Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies

@article{Sun2012BisphosphonateTA,
  title={Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies},
  author={Kai Sun and Jigna Liu and H X Sun and Nan Lu and Guang Ning},
  journal={Osteoporosis International},
  year={2012},
  volume={24},
  pages={279-286}
}
SummaryThe use of bisphosphonates and the risk of esophageal cancer have recently received increasing concern and related studies have yielded controversial results. The present meta-analysis of observational studies shows that no clear association between bisphosphonate treatment and risk of esophageal cancer was observed.IntroductionEpidemiological evidence suggests that bisphosphonate treatment can increase the risk of esophageal cancer. However, data on this issue are unstable and… Expand
Oral bisphosphonates and risk of esophageal cancer : a meta-analysis
Objectives: The association between oral bisphosphonate (BP) intake and esophageal cancer risk has been investigated in several recent studies with conflicting results. Methods: We conducted aExpand
Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis
TLDR
A systematic review and meta-analysis of observational studies and sensitivity analysis of alendronate found no compelling evidence for a significantly raised risk of esophageal cancer or gastric cancer in male and female patients prescribed bisphosphonates. Expand
Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
TLDR
This meta-analysis suggests that the use of bisphosphonates is associated with a reduction in the risk of endometrial cancer but not ovarian cancer. Expand
Bisphosphonates and risk of cancers: a systematic review and meta-analysis
TLDR
Bisphosphonates are significantly associated with risk reduction of colorectal, breast and endometrial cancer, especially nitrogen-containing bisph phosphonates, and large prospective cohort studies are needed to find the causal association between bisph phosphate and risk of cancers. Expand
Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women
TLDR
This meta-analysis adds to the body of evidence for an association between bisphosphonates and a significantly decreased risk of primary BCa, and future large-scale RCTs are required to validate this concern. Expand
Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study
TLDR
The use of oral bisphosphonate was not associated with increased risk of esophageal cancer in real clinical practice using large scale nationwide database. Expand
The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
TLDR
Alendronate therapy may be associated with a high risk of lung cancer, may with an excess risk of liver cancer, a low risk of colorectal and no related risk of other cancers. Expand
Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury
TLDR
Patients age 68 and older with osteoporosis and/or oral bisphosphonate use are studied to identify patients susceptible to early irritating effects; clinicians might offer alternatives and delay endoscopy or antacids. Expand
Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea
TLDR
This study did not prove an increased risk of esophageal or gastric cancer risk associated with bisphosphonate use, with respect to both risk windows and duration of exposure, in an Asian population-based, real-world setting. Expand
Safety issues with bisphosphonate therapy for osteoporosis.
TLDR
Randomized controlled trials have demonstrated the efficacy of bisphosphonates (BP) in improving BMD and reducing fracture risk, but further epidemiological and clinical data are required to establish safety of BP in long-term users and provide evidence-based management. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
An Evaluation of the Use of Oral Bisphosphonates and Risk of Esophageal Cancer
TLDR
Evidence on the use of bisphosphonates and risk of esophageal cancer is weak and conflicting, and health care professionals should ensure that patients take oral bisph phosphonates properly to minimize esophagal irritation. Expand
Oral Bisphosphonate Prescriptions and the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus
TLDR
In patients with BE, oral bisphosphonates were not associated with an increased risk of EAC, and the incidence density ratio was 0.92 (95% CI, 0.21–4.15). Expand
Esophageal and gastric cancer incidence and mortality in alendronate users
TLDR
The early decrease in esophageal cancer rates may relate to the greater use of endoscopy before starting alendronate, and this could lead to more cancers being diagnosed at a stage when their esphageal or gastric location could be accurately distinguished. Expand
Occurrence of Gastrointestinal Cancer in Users of Bisphosphonates and Other Antiresorptive Drugs Against Osteoporosis
TLDR
The association between bisphosphonate use and risk of gastrointestinal (GI) cancers in a nationwide retrospective cohort from Denmark may not be causal as no dose–response or time relationship was present. Expand
Bisphosphonate‐related osteonecrosis of the jaw: an overview
  • S. Ruggiero
  • Medicine
  • Annals of the New York Academy of Sciences
  • 2011
TLDR
The observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized complication and to reevaluate the indications for and the duration of bisphosphonate therapy in patients with osteopenia/osteoporosis and cancer. Expand
Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study
  • C. Chiang, Chin‐Chou Huang, +6 authors H. Leu
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2012
TLDR
Alendronate use was not associated with increased risk of cancer development in women with osteoporosis, and a Cox proportional‐hazard model, adjusted for confounding factors, was used to evaluate the association. Expand
Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis
TLDR
Among older Korean women with osteoporosis, bisphosphonate was found to have a protective effect against atrial fibrillation. Expand
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort
TLDR
The hypothesis that risk of oesophageal, but not of gastric or colorectal, cancer is increased in users of oral bisphosphonates is examined to argue against methodological problems in the selection of cases and controls or in the analysis. Expand
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
TLDR
Although patients using weekly bisphosphonate medication follow their prescribed dosing regimens better than those using daily therapy, overall compliance and persistence rates were suboptimal. Expand
Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
TLDR
Oral bisphosphonate use was associated with significantly lower invasive breast cancer incidence, suggesting bisph phosphonates may have inhibiting effects on breast cancer. Expand
...
1
2
3
4
5
...